Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

被引：0

作者：

Caffo, O. ^{[1
]}

Biasco, E. ^{[2
]}

Facchini, G. ^{[3
]}

Fratino, L. ^{[4
]}

Gasparro, D. ^{[5
]}

Mosillo, C. ^{[6
]}

Maruzzo, M. ^{[7
]}

Santini, D. ^{[8
]}

Tucci, M. ^{[9
]}

Ortega, C. ^{[10
]}

Verderame, F. ^{[11
]}

Scagliarini, S. ^{[12
]}

Lo Re, G. ^{[13
]}

Procopio, G. ^{[14
]}

Fornarini, G. ^{[15
]}

Campadelli, E. ^{[16
]}

Sabbatini, R. ^{[17
]}

Maines, F. ^{[1
]}

De Giorgi, U. ^{[18
]}

机构：

[1] Santa Chiara Hosp, Trento, Italy

[2] Osped Santa Chiara, Pisa, Italy

[3] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Naples, Italy

[4] Ctr Riferimento Oncol, Aviano, Italy

[5] Azienda Osped Univ, Parma, Italy

[6] Univ Roma La Sapienza, Rome, Italy

[7] Ist Oncol Veneto, Padua, Italy

[8] Univ Campus Biomed, Rome, Italy

[9] Osped San Luigi, Orbassano, Italy

[10] IRCCS, Candiolo, Italy

[11] Osped Villa Sofia Cervello, Palermo, Italy

[12] Osped Cardarelli, Naples, Italy

[13] Osped Santa Maria Angeli, Pordenone, Italy

[14] Fdn Ist Nazl Tumori, Milan, Italy

[15] Osped San Martino Genova, Genoa, Italy

[16] Osped Gen, Lugo Di Romagna, Spain

[17] Azienda Osped Univ, Modena, Italy

[18] IRST, Meldola, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw334.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

C09

引用

页数：1

共 50 条

[1] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
Caffo, O.
Biasco, E.
Facchini, G.
Fratino, L.
Gasparro, D.
Mosillo, C.
Basso, U.
Santini, D.
Tucci, M.
Ortega, C.
Verderame, F.
Scagliarini, S.
Lo Re, G.
Procopio, G.
Fornarini, G.
Campadelli, E.
Sabbatini, R.
Maines, F.
De Giorgi, U.
ANNALS OF ONCOLOGY, 2016, 27
[2] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.
Caffo, Orazio
Bria, Emilio
De Giorgi, Ugo
Tucci, Marcello
Galli, Luca
Fratino, Lucia
Rossetti, Sabrina
Iacovelli, Roberto
Lo Re, Giovanni
Mosillo, Claudia
Gasparro, Donatello
Guglielmini, Pamela Francesca
Damiani, Azzurra
Procopio, Giuseppe
De Lisi, Delia
Ruatta, Fiorella
Scagliarini, Sarah
Donini, Maddalena
Sperduti, Isabella
Basso, Umberto
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).
Veccia, Antonello
Caffo, Orazio
Burgio, Salvatore Luca
di Lorenzo, Giuseppe
Ortega, Cinzia
Scognamiglio, Florinda
Mattioli, Rodolfo
Mansueto, Giovanni
Zustovich, Fable
Aieta, Michele
Facchini, Gaetano
Procopio, Giuseppe
D'Angelo, Alessandro
Spizzo, Gilbert
De Giorgi, Ugo
De Placido, Sabino
Ruatta, Fiorella
Galligioni, Enzo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.
Caffo, Orazio
Basso, Umberto
Facchini, Gaetano
Gasparro, Donatello
Alesini, Daniele
Tucci, Marcello
Ortega, Cinzia
Fratino, Lucia
Campadelli, Enrico
Lo Re, Giovanni
Sabbatini, Roberto
Procopio, Giuseppe
Zucali, Paolo A.
D'Angelo, Alessandro
Donini, Maddalena
Massari, Francesco
Ratta, Raffaele
Sava, Teodoro
Messina, Caterina
De Giorgi, Ugo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)
Nadal, Rosa
Zhang, Zhe
Raheja, Hitesh
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[6] Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting
Oudard, S.
Angelergues, A.
Efstathiou, E.
Gonzalez, I.
Gyftaki, R.
Delanoy, N.
Ozguroglu, M.
Flechon, A.
Guillot, A.
Le Moulec, S.
Castellano, D.
Esteban, E.
Munarriz, J.
Campos Balea, B.
Ardavanis, A.
Stefanou, D.
Bellmunt, J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S489 - S489
[7] IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST-DOCETAXEL?
Traina, S.
Li, T.
Johnson, K.
Ho, K. F.
Molina, A.
Cella, D.
VALUE IN HEALTH, 2015, 18 (07) : A470 - A470
[8] Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.
Caffo, Orazio
De Giorgi, Ugo
Ferra, Francesco
Donini, Maddalena
Facchini, Gaetano
Maruzzo, Marco
Tucci, Marcello
Conteduca, Vincenza
Maines, Francesca
Rossi, Lorena
Veccia, Antonello
Galligioni, Enzo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[9] Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.
Maines, Francesca
Caffo, Orazio
Veccia, Antonello
Bria, Emilio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[10] Patient Characteristics and Overall Survival (OS) in the Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) Community Setting
Cheng, Wendy Y.
Miao, Raymond
Duh, Mei Sheng
Vekeman, Francis
Sung, Jennifer
Gauthier-Loiselle, Marjolaine
Fortier, Jonathan
Dhawan, Ravinder
Oh, William K.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 557 - 558

← 1 2 3 4 5 →